Novo Nordisk A/s

Novo Nordisk Healthcare Ag

Christian Rischel

Ole Hvilsted Olsen

Lars Thim

Michael Bech Jensen

Henning Ralf Stennicke

Gert Bolt

Jesper Haaning

Marianne Hjortnes Kjalke

Ditte Maria Karpf

Frederik Rode

Kirstine Roepstorff

Maj Petersen

Anders Dybdal Nielsen

Jens Jacob Hansen

Binow Brit SØRENSEN

The present invention relates to pharmaceutical compositions comprising: (i) at least 10 mg/mL of a Factor VII polypeptide; (ii) a buffering agent suitable for keeping pH in the range of from about 5.0 to about 9.0; (iii) at least one aromatic preservative in a concentration of at least 0.1 mg/mL; and (iv) at least one antioxidant in a concentration of at least 0.1 mg/mL; the composition optionally comprising further components, with the proviso that such further components are not Factor VII polypeptide stabilizing agents selected from (a) metal-containing agents, wherein said metal is selected from the group consisting of first transition series metals of oxidation state +II, except zinc; and (b) stabilizing agents comprising a &#x2014;C(&#x2550;N&#x2014;Z1-R1)-NH&#x2014;Z2-R2 motif.

High concentration factor VII polypeptide formulations comprising an aromatic preservative and an antioxidant

The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.

Compounds suitable for treatment of haemophilia

Growing community of inventors

Copenhagen, Denmark

Christian Rischel